In vitro trichomonacidal activity and preliminary in silico chemometric studies of 5-nitroindazolin-3-one and 3-alkoxy-5-nitroindazole derivatives

What is it about?

Trichomonas vaginalis is a STI (sexually transmitted infection) recently considered as a neglected parasitic infection. With an estimated incidence of more than 276 million infection per year over the world (more than sifilis and gonorrhoea together), little attention is payed by the international health institutions. Only two drugs (metronidazole and tinidazole) are approved by the FDA for trichomonosis treatment, however non other therapeutic alternatives are available for those cases of hipersensitivity, clinical resistance or side effects. In this research we have found an interesting chemical family with remarkable activity against T. vaginalis. These results are the first steps for the identification of novel and promising new chemical alternatives to treat those cases where the use of 5-nitroimidazole are not useful.

Featured Image